EUCTR2014-003856-30-BE进行中（未招募）1 期
Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation.A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR. - SCIROCCO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •GEP NET Ki 67 = 10 %
- •Histologically or cytologically confirmed GEP NET
- •Appearance of carcinoid syndrome maximum 6 months before the inclusion
- •Evaluable or measurable disease (RECIST 1.1)
- •WHO ECOG performance status 0-2
- •Positive somatostatin receptor scintigraphy
- •Life expectancy of at least 12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Uncontrolled concurrent disease which prevents the adequate management and follow-up of the NET.
- •Previous malignancy in the last past 3 years except malignancies estimated as completely cured.
- •Current pregnancy or breast feeding
- •Concomitant anti-tumoral treatment, except external beam radiotherapy
研究者
相似试验
终止
4 期
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation OptimisationNeuroendocrine TumorsCarcinoid SyndromeNCT04140409Cliniques universitaires Saint-Luc- Université Catholique de Louvain10
进行中（未招募）
2 期
Sandostatin LAR in HCCAdvanced Hepatocellular CarcinomaCancer - LiverACTRN12605000699662Site - Investigator Initiated60
进行中（未招募）
不适用
Sandostatin therapy in sarcoidosisSarcoidosisEUCTR2013-005376-17-NLErasmus Medical Center
已完成
2 期
Sandostatin therapy in sarcoidosisSarcoidosis10003816NL-OMON40194Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
1 期
Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancerThe population includes all patients who must have an axillary node dissection for non-metastatic breast cancer.EUCTR2015-004337-27-FRInstitut de Cancérologie de l'Ouest67